The FDA has approved Adzenys XR-ODT (amphetamine extended release oral), from Neos Therapeutics, for the treatment of ADHD in patients...
Neos Therapeutics, Inc. has announced that the FDA approved Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet...
Neos Therapeutics has announced the presentation of new data from a clinical trial of orally disintegrating tablet Cotempla XR-ODT (extended...
Neos Therapeutics has resubmitted a New Drug Application to the FDA for its amphetamine XR orally disintegrating tablet product candidate,...
Biohaven Pharmaceutical and Pfizer Inc. announced positive top-line results from an Asia-Pacific, Phase III clinical trial of Nurtec ODT (rimegepant) in 1,431 adults for the acute treatment of migraine.